Archives of Advances in Biosciences

Johnson KS, Conant EF, Soo MS. Molecular subtypes of breast cancer: a review for breast radiologists. Journal of Breast Imaging. 2021 Jan 1;3(1):12-24. [LINK]

Zhang MH, Man HT, Zhao XD, Dong N, Ma SL. Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials. Biomedical reports. 2014 Jan 1;2(1):41-52. [LINK]

Zubair M, Riaz M, Kiani MN, Aslam HM, Fatima AE, Sultan HM, Rehman AU. Application of nanotechnology for targeted drug delivery and nontoxicity. IJGPN. 2024;2:57-67. [LINK]

Maryam S, Rasheed M, Kareem K, Javed I, Amjad M, Sultan H. Synthesis and function of multi-modality probe for early tumor diagnosis in mouse. AlQalam Journal of Medical and Applied Sciences. 2021 Dec 6;4(2):152-62. [LINK]

Tufail M, Wu C. Exploring the burden of cancer in Pakistan: an analysis of 2019 data. Journal of epidemiology and global health. 2023 Jun;13(2):333-43. [LINK]

Sultan HM, Fatima M, Rehman BU, Sajid T, Riaz M, Mustafa FE, Hassan S, Imran SA. Advances in the probiotic production, innovation, and therapeutic applications in health and nutrition. Trends in Infection and Global Health. 2024;4(2):31-49.[LINK]

Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021 Jun 5;13(11):2824.[LINK]

Chen M, Chen W, Liu D, Chen W, Shen K, Wu J, Zhu L. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer. Breast Cancer. 2022 Sep;29(5):844-53. [LINK]

Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of hematology & oncology. 2022 Sep 8;15(1):129.. [LINK]

Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, Chattopadhyay I, Rao PV, Ghavami S. Autophagy and EMT in cancer and metastasis: Who controls whom?. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2022 Sep 1;1868(9):166431.[LINK]

Sajid T, Jallat Khan ZA, Sultan HM, Mazhar M, Zubair M, Dilshad M, Kareem K. Targeting Cancers: Uncovering the Potential Roles of Potato Tissue Culture as Anti-Cancer Agents—A Secondary Publication. Proceedings of Anticancer Research. 2024;8(3):36-50. [LINK]

Ali M, Shabbir K, Ali S, Mohsin M, Kumar A, Aziz M, Zubair M, Sultan HM. A New Era of Discovery: How Artificial Intelligence has Revolutionized the Biotechnology. Nepal Journal of Biotechnology. 2024 Jul 31;12(1):1-1. [LINK]

Rasheed M, Kareem K, Liaquat A, Ashraf A, Maryam S. Qualitative Proteomics Analysis of Proteins and Biomarkers of Alzheimer’Disease. ASEAN Journal of Science and Engineering. 2022;2(3):217-30. [LINK]

Shazma MZ, Sultan HM, ur Rahman B, Ahmed U, Zehra F, Farooq M. CRISPR-Cas9: A Promising Therapeutic Approach for Diabetes Mellitus. [LINK]

Piergentili R, Basile G, Nocella C, Carnevale R, Marinelli E, Patrone R, Zaami S. Using ncRNAs as tools in Cancer diagnosis and treatment—the way towards personalized medicine to improve patients’ health. International journal of molecular sciences. 2022 Aug 19;23(16):9353. [LINK]

Abubakar M, Ayyoub R, Rehman B, Kiani MN, Ahmed U, Farooq J, Usmani AA. Exploring Novel Therapeutic Breakthroughs for Cancers: Potential Roles of miRNAs. Proceedings of Anticancer Research. 2024;8(5).[LINK]

Sultan H, Javed I, Zubair M, Iqbal K, Bilal M, Iqbal J, Wajid I. Protein and polysaccharide base biomaterial for the formation of composite bone scaffold. AlQalam Journal of Medical and Applied Sciences. 2021 Dec 2;4(2):80-8.[LINK]

Aleena Khalid HM. Anthelmintic Activity of Foeniculum vulgare Seeds and Meta-Analysis of Some Other Medicinal Plants. [LINK]

Yousaf A, Tasneem N, Mustafa A, Fatima R, Nabia N, Khan RA, Abdulbasit H, Abubakar M, Asadullah A, Rizwan R, Baqa-ur-Rehman BU. Gastric cancer associated risk factors and prevalence in Pakistan. ASEAN Journal of Science and Engineering. 2021;1(2):73-8.[LINK]

Riaz M, Zubair M, Iqbal MK, Bukhari SM, Sultan HM. Exploring the platelet and cancer cell interaction in metastasis targeting: Platelets and cancer cell interaction. Journal of Current Oncology and Medical Sciences. 2024 Jun 30;4(2):834-44.[LINK]

Li Y, Li W, Hoffman AR, Cui J, Hu JF. The nucleus/mitochondria-shuttling LncRNAs function as new epigenetic regulators of mitophagy in cancer. Frontiers in Cell and Developmental Biology. 2021 Sep 8;9:699621.[LINK]

Sideris N, Dama P, Bayraktar S, Stiff T, Castellano L. LncRNAs in breast cancer: a link to future approaches. Cancer Gene Therapy. 2022 Dec;29(12):1866-77. [LINK]

Tang J, Wang X, Xiao D, Liu S, Tao Y. The chromatin-associated RNAs in gene regulation and cancer. Molecular Cancer. 2023 Feb 7;22(1):27. [LINK]

Salah Eldeen YM, Ibrahim MM, Kamal DE, AlKaramany AS. Long Non-Coding RNA Hox Transcript Antisense Intergenic RNA (HOTAIR) Possible Roles in Rheumatoid Arthritis. Zagazig University Medical Journal. 2025 Feb 1;31(2):866-75.[LINK]

Wang J, Su Z, Lu S, Fu W, Liu Z, Jiang X, Tai S. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer. Clinica chimica acta. 2018 Oct 1;485:229-33. [LINK]

Song Y, Wang Y, Chen M, Wei Z. HOX transcript antisense intergenic RNA is differentially expressed in hypertrophic scar tissues and regulates the biological function of scar fibroblasts through sponging miR-30a-5p. Dermatologica Sinica. 2023 Jul 1;41(3):160-5.[LINK]

Liguori G, Cerrone M, De Chiara A, Tafuto S, de Bellis MT, Botti G, Di Bonito M, Cantile M. The role of lncRNAs in rare tumors with a focus on Hox transcript antisense RNA (HOTAIR). International Journal of Molecular Sciences. 2021 Sep 21;22(18):10160.[LINK]

Aftab Z, Bukhari SM, Abubakar M, Sultan HM, Zubair M, Abou El Niaaj MA. Innovative Nanoparticle synthesis and multifaceted applications in medicine and cancer therapy. Journal of Clinical and Nursing Research. 2024;8(11):21-35. [LINK]

Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nature Reviews Genetics. 2011 Apr;12(4):283-93.[LINK]

Spitz F, Furlong EE. Transcription factors: from enhancer binding to developmental control. Nature reviews genetics. 2012 Sep;13(9):613-26.[LINK]

Ntini E, Louloupi A, Liz J, Muino JM, Marsico A, Ørom UA. Long ncRNA A-ROD activates its target gene DKK1 at its release from chromatin. Nature communications. 2018 Apr 24;9(1):1636. [LINK]

Di M, Zhang Y, Zeng R, Liu X, Chen W, Zhang M, Zhang C, Li M, Zhang M. The pro-angiogenesis effect of miR33a-5p/Ets-1/DKK1 signaling in ox-LDL induced HUVECs. International Journal of Biological Sciences. 2021 Oct 3;17(15):4122.[LINK]

Giuliani B, Tordonato C, Nicassio F. Mechanisms of long non-coding RNA in breast cancer. International journal of molecular sciences. 2023 Feb 25;24(5):4538. [LINK]

Gil N, Ulitsky I. Regulation of gene expression by cis-acting long non-coding RNAs. Nature Reviews Genetics. 2020 Feb;21(2):102-17.[LINK]

Pirlog R, Drula R, Nutu A, Calin GA, Berindan-Neagoe I. The roles of the colon cancer associated transcript 2 (CCAT2) long non-coding RNA in cancer: a comprehensive characterization of the tumorigenic and molecular functions. International journal of molecular sciences. 2021 Nov 19;22(22):12491.[LINK]

Liau XL, Salvamani S, Gunasekaran B, Chellappan DK, Rhodes A, Ulaganathan V, Tiong YL. CCAT 1-a pivotal oncogenic long non-coding RNA in colorectal cancer. British Journal of Biomedical Science. 2023 Mar 21;80:11103.[LINK]

Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, Zhang S, Wang HB, Ge J, Lu X, Yang L. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell research. 2014 May;24(5):513-31.[LINK]

Zhao W, Song M, Zhang J, Kuerban M, Wang H. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma. International journal of clinical and experimental pathology. 2015 Nov 1;8(11):14131. [PMCID]

Ozawa T, Matsuyama T, Toiyama Y, Takahashi N, Ishikawa T, Uetake H, Yamada Y, Kusunoki M, Calin G, Goel A. CCAT1 and CCAT2 long noncoding RNAs, located within the 8q. 24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer. Annals of Oncology. 2017 Aug 1;28(8):1882-8.[LINK]

Rehman B, Abubakar M, Kiani MN, Ayyoub R. Analysis of Genetic Alterations in TP53 Gene in Breast Cancer—A Secondary Publication. Proceedings of Anticancer Research. 2024;8(3):25-35.[LINK]

Xie X, Tang B, Xiao YF, Xie R, Li BS, Dong H, Zhou JY, Yang SM. Long non-coding RNAs in colorectal cancer. Oncotarget. 2015 Dec 2;7(5):5226. [PMCID]

Wang Y, Liu J, Huang BO, Xu YM, Li J, Huang LF, Lin J, Zhang J, Min QH, Yang WM, Wang XZ. Mechanism of alternative splicing and its regulation. Biomedical reports. 2015 Mar 1;3(2):152-8. [LINK]

Fernandes JC, Acuña SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Non-coding RNA. 2019 Feb 17;5(1):17. [LINK]

Athie-Cuervo A. Somatic Copy-Number Alterations across Human Cancers from LncRNA Perspective. [LINK]

Hasler D, Meister G, Fischer U. Stabilize and connect: the role of LARP7 in nuclear non-coding RNA metabolism. RNA biology. 2021 Feb 1;18(2):290-303.[LINK]

Zhao P, Sablina A. Multi-omics approaches to elucidate the role of non-coding genome in cancer.[LINK]

De Troyer L, Zhao P, Pastor T, Baietti MF, Barra J, Vendramin R, Dok R, Lechat B, Najm P, Van Haver D, Impens F. Stress-induced lncRNA LASTR fosters cancer cell fitness by regulating the activity of the U4/U6 recycling factor SART3. Nucleic acids research. 2020 Mar 18;48(5):2502-17. [LINK]

Zhou ZR, Wang XY, Yu XL, Mei X, Chen XX, Hu QC, Yang ZZ, Guo XM. Building radiation-resistant model in triple-negative breast cancer to screen radioresistance-related molecular markers. Annals of Translational Medicine. 2020 Feb;8(4):108.[PMCID]

Kumar V, Shaulian E. LncRNAs, Critical Regulators of Cellular Stress in Cancer: A New Player in the Old Game. Journal of Cellular Signaling. 2024 Sep 24;5(3):143-8. [LINK]

Jen J, Tang YA, Lu YH, Lin CC, Lai WW, Wang YC. Oct4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Molecular cancer. 2017 Jun 14;16(1):104.[LINK]

Sun Y, Ma L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers. 2019 Feb 13;11(2):216. [LINK]

Alshahrani MY, Saleh RO, Hjazi A, Bansal P, Kaur H, Deorari M, Altalbawy FM, Kareem AH, Hamzah HF, Mohammed BA. Molecular mechanisms of tumorgenesis and metastasis of long non-coding RNA (lncRNA) NEAT1 in human solid tumors; An update. Cell Biochemistry and Biophysics. 2024 Jun;82(2):593-607. [LINK]

Zhou Q, Liu L, Zhou J, Chen Y, Xie D, Yao Y, Cui D. Novel insights into MALAT1 function as a MicroRNA sponge in NSCLC. Frontiers in Oncology. 2021 Oct 27;11:758653. [LINK]

Nakagawa S, Ip JY, Shioi GO, Tripathi V, Zong X, Hirose T, Prasanth KV. Malat1 is not an essential component of nuclear speckles in mice. Rna. 2012 Aug 1;18(8):1487-99.[PMID]

Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. Journal of molecular medicine. 2013 Jul;91(7):791-801. [LINK]

Khan M, Hou S, Chen M, Lei H. Mechanisms of RNA export and nuclear retention. Wiley Interdisciplinary Reviews: RNA. 2023 May;14(3):e1755.[LINK]

Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, Li B. New insights into the interplay between long non‐coding RNAs and RNA‐binding proteins in cancer. Cancer communications. 2022 Feb;42(2):117-40.[LINK]

Chiu HS, Martínez MR, . Komissarova EV, Llobet-Navas D, Bansal M, Paull EO, Silva J, Yang X, Sumazin P, Califano A. The number of titrated microRNA species dictates ceRNA regulation. Nucleic acids research. 2018 May 18;46(9):4354-69. [LINK]

Zhao Y, Teng H, Yao F, Yap S, Sun Y, Ma L. Challenges and strategies in ascribing functions to long noncoding RNAs. Cancers. 2020 Jun 3;12(6):1458.[PMCID]

Yuan Y, Ren X, Xie Z, Wang X. A quantitative understanding of microRNA-mediated competing endogenous RNA regulation. Quantitative Biology. 2016 Mar;4(1):47-57.[LINK]

Abubakar M, Ayyoub R, Rehman B, Zubair M, Ahmed U. Advancing cancer stem cell-targeted therapeutic applications. Proceedings of Anticancer Research. 2024;8(5).[LINK]

Tsagakis I, Douka K, Birds I, Aspden JL. Long non‐coding RNAs in development and disease: conservation to mechanisms. The Journal of pathology. 2020 Apr;250(5):480-95. [LINK]

Chen YM, Liu Y, Wei HY, Lv KZ, Fu P. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells. Tumor Biology. 2016 Aug;37(8):10861-70.[LINK]

Zaman A, Sultan HM, Malik NU, Waseem R, Farooq J. Characterization of blaNDM Gene in Multidrug-Resistant Pathogens. [LINK]

Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y, Zhao L, Zhang Y, Huang B, Lu J. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell death & disease. 2014 Jun;5(6):e1287-. [LINK]

Usman M, Hameed Y, Ahmad M, Iqbal MJ, Maryam A, Mazhar A, Naz S, Tanveer R, Saeed H, Ashraf A, Hadi A. SHMT2 is associated with tumor purity, CD8+ T immune cells infiltration, and a novel therapeutic target in four different human cancers. Current Molecular Medicine. 2023 Feb 1;23(2):161-76.[LINK]

Zou F, Rao T, Chen W, Song T, Li T, Hu W, Li L, Yu W, Cheng F. DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7. Cellular Signalling. 2023 Dec 1;112:110893.[LINK]

Vennin C, Dahmani F, Spruyt N, Adriaenssens E. Role of long non-coding RNA in cells: Example of the H19/IGF2 locus. [LINK]

Chang S. Developmental Role of H19 and IGF2 in Mouse and Human (Doctoral dissertation, University of Pennsylvania).[LINK]

Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non‐coding RNA in growth and development. Bioessays. 2010 Jun;32(6):473-80.[LINK]

Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Völkel P, Angrand PO, Winter M, Bertucci F, Finetti P, Lagadec C. Enhancement of breast cancer cell aggressiveness by lncRNA H19 and its Mir-675 derivative: insight into shared and different actions. Cancers. 2020 Jun 29;12(7):1730.[LINK]

Liu C, Chen Z, Fang J, Xu A, Zhang W, Wang Z. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation. Tumor Biology. 2016 Jan;37(1):263-70.[LINK]

Ma Y, Shen N, Wicha MS, Luo M. The roles of the Let-7 family of MicroRNAs in the regulation of cancer stemness. Cells. 2021 Sep 14;10(9):2415.[LINK]

Fletcher CE, Deng L, Orafidiya F, Yuan W, Lorentzen MP, Cyran OW, Varela-Carver A, Constantin TA, Leach DA, Dobbs FM, Figueiredo I. A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Molecular Cancer. 2022 Mar 22;21(1):82.[LINK]

Zhang T, Huang H, Liang L, Lu H, Liang D. Long non-coding RNA (LncRNA) non-coding RNA activated by DNA damage (NORAD) knockdown alleviates airway remodeling in asthma via regulating miR-410-3p/RCC2 and inhibiting Wnt/β-catenin pathway. Heliyon. 2024 Jan 15;10(1).[LINK]

Yang Z, Zhao Y, Lin G, Zhou X, Jiang X, Zhao H. Noncoding RNA activated by DNA damage (NORAD): Biologic function and mechanisms in human cancers. Clinica chimica acta. 2019 Feb 1;489:5-9.[LINK]

Soghli N, Yousefi T, Abolghasemi M, Qujeq D. NORAD, a critical long non-coding RNA in human cancers. Life Sciences. 2021 Jan 1;264:118665.[LINK]

Huang C, Liu J, He L, Wang F, Xiong B, Li Y, Yang X. The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development. Bioengineered. 2021 Dec 20;12(2):11738-55. [LINK]

Guo B, Wu S, Zhu X, Zhang L, Deng J, Li F, Wang Y, Zhang S, Wu R, Lu J, Zhou Y. Micropeptide CIP 2A‐BP encoded by LINC 00665 inhibits triple‐negative breast cancer progression. The EMBO journal. 2020 Jan 2;39(1):e102190.[LINK]

Li YR, Zong RQ, Zhang HY, Meng XY, Wu FX. Mechanism analysis of LINC00665 and its peptides CIP2A-BP in hepatocellular carcinoma. Frontiers in Genetics. 2022 Mar 8;13:861096.[LINK]

Zhong C, Xie Z, Shen J, Jia Y, Duan S. LINC00665: an emerging biomarker for cancer diagnostics and therapeutics. Cells. 2022 May 4;11(9):1540. [LINK]

Itoh M, Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. Journal of mammary gland biology and neoplasia. 2003 Oct;8(4):449-62. [LINK]

Ticli G, Cazzalini O, Stivala LA, Prosperi E. Revisiting the function of p21CDKN1A in DNA repair: the influence of protein interactions and stability. International journal of molecular sciences. 2022 Jun 24;23(13):7058. [LINK]

Saramaki A, Diermeier S, Kellner R, Laitinen H, Vaisanen S, Carlberg C. Cyclical chromatin looping and transcription factor association on the regulatory regions of the p21 (CDKN1A) gene in response to 1α, 25-dihydroxyvitamin D3. Journal of Biological Chemistry. 2009 Mar 20;284(12):8073-82. [LINK]

Sultan HM, Zubair M, Ashraf A. A COMPREHENSIVE REVIEW ON EXPLORING THE SIGNIFICANCE OF MYCOVIRUSES. Pakistan Journal of Phytopathology. 2024 Jan 1;36(1). [LINK]

Li T, Meng XL, Yang WQ. Long noncoding RNA PVT1 acts as a “Sponge” to inhibit microRNA-152 in gastric cancer cells. Digestive Diseases and Sciences. 2017 Nov;62(11):3021-8.[LINK]

Zhou Q, Chen F, Zhao J, Li B, Liang Y, Pan W, Zhang S, Wang X, Zheng D. Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. Oncotarget. 2016 Nov 2;7(50):82620.[PMCID]

Ghetti M, Vannini I, Storlazzi CT, Martinelli G, Simonetti G. Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. Molecular cancer. 2020 Mar 30;19(1):69. [LINK]

Conte F, Fiscon G, Chiara M, Colombo T, Farina L, Paci P. Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer. PloS one. 2017 Feb 10;12(2):e0171661. [LINK]

Abubakar M, Rehman B. Roles of mutant TP53 gene in cancer development and progression. Proceedings of Anticancer Research. 2024;8(5):165-81.[LINK]

Ju JK, Han WN, Shi CL. Long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 gene (PVT1) modulates the proliferation and apoptosis of acute lymphoblastic leukemia cells by sponging miR-486-5p. Bioengineered. 2022 Feb 1;13(2):4587-97. [LINK]

Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clinical cancer research. 2007 Oct 1;13(19):5745-55. [LINK]

Cho SW, Xu J, Sun R, Mumbach MR, Carter AC, Chen YG, Yost KE, Kim J, He J, Nevins SA, Chin SF. Promoter of lncRNA gene PVT1 is a tumor-suppressor DNA boundary element. Cell. 2018 May 31;173(6):1398-412. [LINK]

Vízkeleti L, Spisák S. Rewired metabolism caused by the oncogenic deregulation of MYC as an attractive therapeutic target in cancers. Cells. 2023 Jun 29;12(13):1745.[LINK]

Meyer KB, Maia AT, O'Reilly M, Ghoussaini M, Prathalingam R, Porter-Gill P, Ambs S, Prokunina-Olsson L, Carroll J, Ponder BA. A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression. PLoS genetics. 2011 Jul 21;7(7):e1002165. [LINK]

Tesfaye E, Martinez-Terroba E, Bendor J, Winkler L, Olivero C, Chen K, Feldser DM, Zamudio JR, Dimitrova N. The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs. Proceedings of the National Academy of Sciences. 2021 Aug 3;118(31):e2025539118.[LINK]

Meek DW. Regulation of the p53 response and its relationship to cancer. Biochemical Journal. 2015 Aug 1;469(3):325-46.[LINK]

Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. Journal of Biological Chemistry. 2012 Jan 1;287(4):2509-19. [LINK]

Ferrer J, Dimitrova N. Transcription regulation by long non-coding RNAs: mechanisms and disease relevance. Nature Reviews Molecular Cell Biology. 2024 May;25(5):396-415.[LINK]

Jin K, Wang S, Zhang Y, Xia M, Mo Y, Li X, Li G, Zeng Z, Xiong W, He Y. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis. Cellular and Molecular Life Sciences. 2019 Nov;76(21):4275-89.[PMID]

Parolia A, Cieślik M, Chinnaiyan AM. Competing for enhancers: PVT1 fine-tunes MYC expression. Cell Research. 2018 Jul 6;28(8):785. [PMID]

Olivero CE, Martínez-Terroba E, Zimmer J, Liao C, Tesfaye E, Hooshdaran N, Schofield JA, Bendor J, Fang D, Simon MD, Zamudio JR. p53 activates the long noncoding RNA Pvt1b to inhibit Myc and suppress tumorigenesis. Molecular cell. 2020 Feb 20;77(4):761-74.[PMID]

Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Molecular cell. 2011 Sep 16;43(6):904-14.[PMID]

Fuschi P, Carrara M, Voellenkle C, Garcia-Manteiga JM, Righini P, Maimone B, Sangalli E, Villa F, Specchia C, Picozza M, Nano G. Central role of the p53 pathway in the noncoding-RNA response to oxidative stress. Aging (Albany NY). 2017 Dec 12;9(12):2559.[PMID]

Zhang A, Xu M, Mo YY. Role of the lncRNA–p53 regulatory network in cancer. Journal of molecular cell biology. 2014 Jun 1;6(3):181-91.[PMID]